Doubts as to the cardiovascular safety of rosiglitazone;Twijfels aan de cardiovasculaire veiligheid van rosiglitazon

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 26, 2007, Pages 1449-1450

  Hoekstra, J B L ^a   Bossuyt, P M M ^a   De Vries, J H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

CARDIOVASCULAR RISK; DRUG SAFETY; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; SAFETY; THIAZOLIDINEDIONES;

EID: 34447284965     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Hampton T. Diabetes drugs tied to fractures in women. JAMA. 2007; 297:1645.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. [ter perse].
3. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Lancet. 2006;368:1096-105.
4. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia. 2005;48:1726-35.
5. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-54.
6. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. PROactive Investigators. Lancet. 2005;386:1279-89.
7. Rutten GEHM, Grauw WJC de, Nijpels G, Goudswaard AN, Uitewaal PJM, Does FEE van der, et al. NHG-standaard Diabetes mellitus type 2 (tweede herziening). Huisarts Wet. 2006;49:137-52.
8. Tack CJ, Smits P. Plaats van thiazolidinedionen bij diabetes mellitus type 2. Geneesmiddelenbulletin. 2005;39:33-140.
9. Holleman F, Gerdes VEA, Vries JH de, Hoekstra JBL. Onderzoek naar pioglitazon als secundaire preventie van cardiovasculaire gebeurtenissen bij patienten met diabetes mellitus type 2: onvoldoende bewijs. Ned Tijdschr Geneeskd. 2006;150:358-60.
10. Laan J van der, Walma E. Onvoldoende bewijs voor thiazolidinederivaten bij diabetes mellitus. Huisarts Wet. 2007;50:116-7.